We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+31.09%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$9.98B
AUM Growth
+$1.87B
Cap. Flow
+$293M
Cap. Flow %
2.94%
Top 10 Hldgs %
50.46%
Holding
103
New
29
Increased
20
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$321M
2
IRTC icon
iRhythm Holdings
IRTC
+$209M
3
APLS
Apellis Pharmaceuticals
APLS
+$180M
4
RGEN icon
Repligen
RGEN
+$167M
5
COGT icon
Cogent Biosciences
COGT
+$116M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$496M
2
AKRO
Akero Therapeutics
AKRO
+$260M
3
MRUS
Merus
MRUS
+$191M
4
NTRA icon
Natera
NTRA
+$104M
5
SYK icon
Stryker
SYK
+$89.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$12.8B
$1.16B 11.63%
1,993,687
– –
INSM icon
2
Insmed
INSM
$22.9B
$843M 8.44%
4,842,879
+1,758,321
+57% +$321M
PTCT icon
3
PTC Therapeutics
PTCT
$6.33B
$588M 5.89%
7,746,415
– –
ARGX icon
4
argenx
ARGX
$56.1B
$566M 5.67%
673,497
– –
PTGX icon
5
Protagonist Therapeutics
PTGX
$8.75B
$442M 4.43%
5,059,053
-697,224
-12% -$57.1M
NTRA icon
6
Natera
NTRA
$37.2B
$344M 3.44%
1,500,000
-500,000
-25% -$104M
RDNT icon
7
RadNet
RDNT
$4.85B
$281M 2.81%
3,938,500
+1,122,956
+40% +$86.7M
TARS icon
8
Tarsus Pharmaceuticals
TARS
$2.65B
$273M 2.74%
3,335,320
+157,884
+5% +$11.8M
COGT icon
9
Cogent Biosciences
COGT
$6.9B
$270M 2.7%
7,592,241
+4,124,755
+119% +$116M
PEN icon
10
Penumbra
PEN
$12.6B
$269M 2.7%
866,499
– –
IRTC icon
11
iRhythm Holdings
IRTC
$3.71B
$210M 2.1%
+1,181,990
New +$209M
APGE icon
12
Apogee Therapeutics
APGE
$10.2B
$205M 2.05%
2,712,097
– –
APLS
13
DELISTED
Apellis Pharmaceuticals
APLS
$193M 1.93%
+7,666,764
New +$180M
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$4.4B
$191M 1.91%
7,144,524
– –
ESTA icon
15
Establishment Labs
ESTA
$2.7B
$189M 1.89%
2,588,831
– –
STOK icon
16
Stoke Therapeutics
STOK
$1.84B
$176M 1.76%
5,546,856
+423,331
+8% +$12.7M
RGEN icon
17
Repligen
RGEN
$7.39B
$174M 1.75%
+1,064,000
New +$167M
CYTK icon
18
Cytokinetics
CYTK
$11B
$173M 1.73%
2,721,158
– –
IMCR icon
19
Immunocore
IMCR
$1.74B
$169M 1.69%
4,869,798
– –
AXSM icon
20
Axsome Therapeutics
AXSM
$12.3B
$162M 1.62%
888,001
-230,882
-21% -$32.2M
GH icon
21
Guardant Health
GH
$19.1B
$151M 1.52%
1,481,033
– –
NBIX icon
22
Neurocrine Biosciences
NBIX
$17.8B
$151M 1.51%
1,062,072
– –
SYRE icon
23
Spyre Therapeutics
SYRE
$8.71B
$137M 1.37%
4,171,996
+550,000
+15% +$14.4M
ZLAB icon
24
Zai Lab
ZLAB
$2.11B
$123M 1.23%
6,959,032
+4,667,660
+204% +$109M
IMTX icon
25
Immatics
IMTX
$1.21B
$120M 1.2%
11,433,354
+2,617,737
+30% +$26.4M
1
2 3 4 5

Similar funds

LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return

RTW Investments's Q4 2025 Portfolio in Review

As of Q4 2025, RTW Investments held 103 positions worth $9.98B, up 23% from $8.12B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments's Q4 2025 filing shows 29 new, 20 increased, 12 reduced and 12 closed positions. Its largest new stake was iRhythm Holdings: 1,181,990 shares worth $210M. The largest sale was Avidity Biosciences, an estimated $496M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q4 2025 buy was iRhythm Holdings: 1,181,990 shares worth $210M.
  • RTW Investments added most to Insmed in Q4 2025, an estimated $321M increase.
  • RTW Investments's biggest Q4 2025 reduction was Natera, cutting an estimated $104M.
  • RTW Investments fully exited Avidity Biosciences in Q4 2025, selling an estimated $496M.
  • RTW Investments's ten largest holdings make up 50% of its $9.98B portfolio in Q4 2025.
  • RTW Investments opened 29 new positions and closed 12 in Q4 2025.
  • RTW Investments's portfolio value rose 23% quarter-over-quarter to $9.98B.

Based on RTW Investments's 13F filing for Q4 2025, filed 17 Feb 2026.